Expansion of Pharmacy Prescribing in England
More pharmacists in England will be authorized to prescribe medications as part of an initiative aimed at accelerating patient care and alleviating the workload on GP surgeries and hospitals.
Currently, under the Pharmacy First scheme, pharmacists can prescribe medication for conditions including sore throat, earache, sinusitis, shingles, impetigo, infected bites, and urinary tract infections.
Starting this autumn, a new investment of £340 million will enable pharmacists to prescribe for five additional common ailments, although the specific conditions have not yet been disclosed.
Despite this expansion, the National Pharmacy Association (NPA) has expressed concerns that the agreement does not sufficiently address increasing business rates, employer costs, and medicine prices.
Background and Current Scope of Pharmacy First
The Pharmacy First scheme in England was initially launched in 2024. It allows patients to consult their pharmacist for advice, over-the-counter treatments, and prescription-only medications.
In addition to medication, patients can visit pharmacies for eye, ear, oral, and dental care, as well as treatment for digestive issues.
According to the Department of Health and Social Care, over 3.3 million consultations under the scheme were conducted between March 2025 and February 2026.
Government Perspective
Health Minister Stephen Kinnock emphasized the government's commitment to utilizing pharmacists' expertise and enhancing access to healthcare services.
"The government is making the most of our highly skilled pharmacists, while boosting access to services and giving patients more care right on their doorstep."
"Independent prescribing will play a major part in delivering this shift, easing pressures on GPs, cutting unnecessary red tape and helping patients get the right care closer to home," he added.
Concerns from the National Pharmacy Association
The NPA acknowledged that the deal is a step forward but criticized it for not addressing the significant financial challenges facing pharmacies.
"While the deal points in the right direction, it did very little to close the £2.5bn funding gap that the NHS itself identified a year ago," said NPA chairman Dr Olivier Picard.
"The expanded scheme is nowhere near ambitious enough to transform patient access to care, nor make full use of pharmacists' skills."
Dr Picard further expressed worries about the sustainability of the scheme given current funding levels.
"We are also concerned that the current funding levels mean that many pharmacies will struggle to take this development forwards, risking its success. Pharmacies cannot sustain yet more loss-making work."
